Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADME study of [14C]-STX-478 in healthy men
NCT06901336Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Mar 2025
- Primary completion
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of tersolisib in solid tumor (advanced stage), breast cancer and gynecologic cancer, sponsored by Eli Lilly and Company. Primary endpoint: Percentage of the Total Radioactive Dose in Urinary, Fecal, and Urinary and Fecal Combined Excretion. Started Mar 2025; status: completed.
02
Drugs
tersolisib
03
Conditions
solid tumor (advanced stage)breast cancergynecologic cancer
Beyond the preview
Go deeper on NCT06901336.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06901336.